Apollomics_Logos Final-01.png
Apollomics Inc. Announces Official Opening of Shanghai Branch
May 20, 2021 10:19 ET | Apollomics, Inc.
FOSTER CITY, Calif. and SHANGHAI and HANGZHOU, China, May 20, 2021 (GLOBE NEWSWIRE) -- Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono-...
Apollomics_Logos Final-01.png
Apollomics, Inc. Appoints Seasoned Healthcare Executive K. Peony Yu, M.D., as Chief Medical Officer
March 09, 2021 07:10 ET | Apollomics, Inc.
- Fibrogen veteran brings global R&D expertise to Management Team - - Merck KGaA Executive Sophie (Zhengjie) Sun named Senior Vice President, Corporate Development bringing partnership, strategy...
Apollomics_Logos Final-01.png
Apollomics, Inc. Announces Successful Enrollment of First Patient Into Phase 1 Clinical Trial of APL-106 (Uproleselan Injection) in China
March 04, 2021 07:10 ET | Apollomics, Inc.
FOSTER CITY, Calif. and HANGZHOU, ZHEJIANG, China, March 04, 2021 (GLOBE NEWSWIRE) -- Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono-...
Apollomics_Logos Final-01.png
Apollomics, Inc. Licenses a Targeted, Active Checkpoint Control Immunotherapy for Greater China and South Africa
February 12, 2021 07:10 ET | Apollomics, Inc.
FOSTER CITY, Calif. and HANGZHOU, ZHEJIANG, China, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and...
Apollomics_Logos Final-01.png
Apollomics, Inc. and Iterion Therapeutics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Tegavivint in Greater China
February 10, 2021 07:10 ET | Apollomics, Inc.
FOSTER CITY, Calif., HANGZHOU, China and HOUSTON, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and...
Apollomics_Logos Final-01.png
Apollomics, Inc. and Edison Oncology Announce Licensing Agreement for Novel Protein Tyrosine Kinase Inhibitor Targeting Solid Tumors
February 09, 2021 07:10 ET | Apollomics, Inc.; Edison Oncology
- Apollomics licenses worldwide rights (ex-China, Hong Kong and Taiwan) to develop and commercialize EO1001 - - EO1001 is an irreversible, pan-erbB inhibitor of EGFR (ErbB1), HER2 (ErbB2) and...
Apollomics_Logos Final-01.png
APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia
January 07, 2021 07:10 ET | Apollomics, Inc.
FOSTER CITY, Calif. and HANGZHOU, China and GAITHERSBURG, Md., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development...
Apollomics_Logos Final-01.png
Apollomics, Inc. Receives China Investigational New Drug Approval for APL-102 to Initiate a Phase 1 Study
November 12, 2020 07:10 ET | Apollomics, Inc.
FOSTER CITY, Calif. and HANGZHOU, China, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of new tumor-targeting...
Apollomics_Logos Final-01.png
Apollomics, Inc. Closes $124 Million Series C Financing
November 06, 2020 07:10 ET | Apollomics, Inc.
- Financing led by Ping An Capital - - Phase 2 SPARTA Trial for APL-101 Now Enrolling - - Phase 3 Clinical Trial to begin in China for APL-106 (Uproleselan) - FOSTER CITY, Calif. and HANGZHOU,...
Apollomics_Logos Final-01.png
Apollomics, Inc. Receives China Investigational New Drug Approval for APL-106 to Initiate a Phase 3 Bridging Study in Acute Myeloid Leukemia
September 27, 2020 20:05 ET | Apollomics, Inc.
FOSTER CITY, Calif. and HANGZHOU, China, Sept. 27, 2020 (GLOBE NEWSWIRE) -- Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and...